NCT00850044 - Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

July 31, 2009

Conditions

HCV Infection

Interventions

DRUG

ABT-450

capsules,QD, one dose, see Arm Descriptions for more information

DRUG

ritonavir

capsules, QD, one dose, escalating doses, see Arm Descriptions for more information

DRUG

placebo for ABT-450

capsules, QD, one dose

DRUG

Placebo for ritonavir

capsules, QD, one dose

Trial Locations (1)

Site Reference ID/Investigator# 15981, Waukegan